We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Bifidobacterium breve CCFM1025 Improves Sleep Quality via Regulating the Activity of the HPA Axis: A Randomized Clinical Trial.
- Authors
Lan, Yuming; Lu, Junjie; Qiao, Guohong; Mao, Xuhua; Zhao, Jianxin; Wang, Gang; Tian, Peijun; Chen, Wei
- Abstract
Psychobiotics, a newly identified category of probiotics primarily targeting the gut–brain axis, exhibit tremendous potential in improving sleep quality. In this study, the clinical trial was registered in advance (identifier: NO. ChiCTR2300067806). Forty participants who were diagnosed with stress-induced insomnia were chosen and randomly divided into two groups: one received CCFM1025 at a dose of 5 × 109 CFU (n = 20), while the other was administered a placebo (n = 20), over a period of four weeks. The results revealed that compared to the placebo group (pre: M = 10.10, SD = 2.292; post: M = 8.650, SD = 2.793; pre vs. post: F (1, 38) = 15.41, p = 0.4316), the CCFM1025-treated group exhibited a significant decrease in Pittsburgh Sleep Quality Index (PSQI) scores from baseline (pre: M = 11.60, SD = 3.169; post: M = 7.750, SD = 3.697, F (1, 38) = 15.41, p = 0.0007). Furthermore, the administration of CCFM1025 was associated with a more pronounced reduction in stress marker concentrations. This effect could potentially be linked to changes in serum metabolites induced by the probiotic treatment, notably daidzein. In conclusion, B. breve CCFM1025 demonstrates promise as a psychobiotic strain for enhancing sleep quality.
- Subjects
BIFIDOBACTERIUM; SLEEP quality; HYPOTHALAMIC-pituitary-adrenal axis; RANDOMIZED controlled trials; PLACEBOS; COMPARATIVE studies; PROBIOTICS; QUALITY assurance; RESEARCH funding; STATISTICAL sampling
- Publication
Nutrients, 2023, Vol 15, Issue 21, p4700
- ISSN
2072-6643
- Publication type
Article
- DOI
10.3390/nu15214700